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CHANGING	LANDSCAPE	OF	IMMUNO-ONCOLOGY:	
CAR-T	THERAPY	AND	PD1/PDL1	BLOCKADE	
NAVEEN	KUMAR	MUNAGALA	REDDY	ABSTRACT		 The	current	field	of	cancer	treatment	is	undergoing	a	revolution.	The	influx	of	novel	therapies	derived	from	basic	research	on	the	immune	system	has	shifted	the	landscape	of	modern	medicine.	Immunotherapy	seeks	to	use	the	body’s	own	immune	system	as	a	medium	to	terminate	neoplastic	cells.	This	is	performed	by	manipulating	the	immune	system	into	either	targeting	cancer	antigens	or	breaking	down	barriers	towards	T	cell	infiltration.	The	former	mechanism	uses	CAR-T	cells	as	an	instrument	to	target	specific	cancer	neo-antigens.	CAR-T	cells	begin	as	T	cells	derived	from	a	patient’s	immune	system.	These	cells	are	removed	from	the	body	and	engineered	to	express	a	chimeric	antigen	receptor	(CAR)	through	a	process	of	viral	transduction.	This	CAR	allows	the	T	cell	to	recognize	and	bind	to	a	specific	antigen	of	interest.	In	most	cases,	the	antigen	is	present	on	cancer	cells.	The	T	cells,	now	expressing	the	CAR	receptor,	are	transplanted	back	into	the	body	of	the	patient	and	proceed	to	target	cancer	cells.	This	therapy	has	been	used	in	hematological	malignancies	to	great	effect.	Applying	CAR-T	cells	to	solid	tumors	is	an	ongoing	process,	but	has	been	difficult	to	establish	due	to	the	immunosuppressive	aspects	of	the	tumor	microenvironment.	As	such,	combining	CAR-T	cells	with	traditional	anti-cancer	therapies	has	been	proven	to	be	efficacious	in	treating	patients	with	solid	tumors.	In	general,	immunosuppression	is	a	large	problem	in	the	treatment	of	
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cancer.	Cancer	cells	and	the	tumor	microenvironment	express	receptors	that	downregulate	tumor-targeting	actions	of	the	immune	system.		The	discovery	of	the	programmed	cell	death	protein	1	(PD1)	allowed	researchers	to	create	novel	antibodies	that	inhibit	immunosuppression.	PD1	located	on	T	cells,	binds	to	PDL1	on	cancer	and	stromal	cells.	This	interaction	induces	exhaustion	and	anergy	in	infiltrating	T	cells,	thereby	prevent	T	cells	from	targeting	cancer	cells.	As	such,	the	newly	approved	checkpoint	blockade	antibodies,	Nivolumab	and	Pembrolizumab,	block	this	interaction	and	allow	T	cells	to	carry	out	their	targeting	function.	CAR-T	cells	and	checkpoint	blockade	have	both	seen	immense	success	in	clinical	trials	and	are	currently	being	used	the	clinic.	Nonetheless,	development	of	these	therapies	for	different	types	of	cancers	is	an	ongoing	process	and	one	that	will	require	immense	effort	on	behalf	of	the	medical	and	pharmaceutical	establishment	.		 	
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INTRODUCTION			 The	treatment	of	cancer	has	become	a	prime	concern	of	the	modern	medical	and	pharmaceutical	establishment.	In	2016	alone,	more	than	two	million	individuals	in	the	United	States	will	be	diagnosed	with	cancer	and	six	hundred	thousand	patients	will	die	from	the	disease	(1).	To	put	this	into	perspective,	approximately	forty	percent	of	all	individuals	in	the	United	States	will	contract	the	disease	in	their	lifetime	and	more	than	half	of	all	Americans	will	eventually	succumb	to	its	effects.	As	such,	immense	efforts	and	resources	have	been	poured	into	cancer	therapies.		In	2010,	national	expenditure	on	cancer	treatment	totaled	125	billion	dollars	and	is	expected	to	reach	156	billion	in	2020	(1).	However,	there	is	a	positive	side	to	these	disconcerting	values.	The	overall	cancer	death	rate	has	been	steadily	decreasing	(2).	Specifically,	a	two	percent	decrease	in	cancer	mortality	has	been	shown	between	2002	and	2011	(2).	This	can	be	attributed	to	a	lower	incidence	of	smoking	and	the	creation	of	better	anti-cancer	therapies.	However,	the	increased	prevalence	of	obesity,	pollution,	and	an	aging	population,	all	risk	factors,	pose	a	challenge	to	both	the	current	and	future	political,	economical,	and	medical	institutions	(1).			 As	our	understanding	of	cancer	has	grown,	so	to	has	our	ability	to	fight	the	disease.	Cancer,	at	its	core,	is	a	genetic	disease	that	seeks	to	outmaneuver	the	body’s	ability	to	recognize	abnormal	cell	proliferation	(3).	In	other	pathogenic	diseases,	the	immune	system	is	able	to	recognize	and	terminate	cells	expressing	foreign	antigens.	In	cancer,	however,	the	tumor	is	a	propagation	of	native	tissue	and	thus,	does	
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normally	express	foreign	antigens	(3).	As	such,	the	tumor	can	continuously	grow	under	the	guise	of	normal	tissue.	Most	chemotherapy	and	radiation	interventions	from	the	1920’s	and	onward	focused	on	killing	cancer	cells	through	brute	force	(3).	These	therapies	targeted	all	of	the	body’s	highly	proliferative	cells.	As	a	consequence,	the	tumor	would	shrink	in	size	but	with	side	effects	of	healthy	tissue	death	and	bodily	sickness.	As	research	into	the	body’s	immune	system	grew,	scientists	recognized	that	immune	cells	could	be	reprogrammed	and	altered	to	target	specific	cancer	antigens.	As	such,	the	modern	field	of	immunotherapy	(1980’s	onward)	provides	a	novel	and	powerful	means	to	selectively	target	and	destroy	cancer	cells	(4).	This	paper	will	elucidate	the	history,	mechanism	of	action,	efficacy,	and	future	of	two	promising	trends	in	immunotherapy:	CAR-T	cells	and	checkpoint	blockade		
History	Of	CAR-T	Therapy		 CAR-T	cells	are	T	cells	that	have	been	engineered	to	detect	and	eradicate	tumor	cells.		The	history	of	CAR-T	cells	can	be	first	traced	back	to	1988	when	Dr.	Steven	Rosenberg	discovered	that	a	small	subset	of	tumor-infiltrating	lymphocytes	(TILs)	were	immunogenic	towards	melanoma	cancer	cells	(4).	He	showed	the	existence	of	a	population	of	T	cells	that	specifically	targeted	melanoma	cells	without	off-target	effects.	Rosenberg’s	group	selectively	isolated	these	tumor	specific	TILs,	expanded	them	ex	vivo,	and	re-inserted	them	into	the	patient	(4).	The	response	was	robust	as	the	patient’s	tumor	burden	dramatically	reduced	without	significant	off-
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target	effects	(4).	Rosenberg	sought	to	expand	this	therapy	to	other	cancer	types	but	in	1992,	came	to	the	conclusion	that	TILs	are	not	present	in	most	cancers	(4).	Moreover,	only	about	half	of	Melanoma	patients	have	these	tumor	specific	T	cells	(4).	Nonetheless,	this	initial	discovery	caused	an	explosion	in	the	field	of	cancer	immunotherapy.	As	a	first	step,	in	2003	the	genetic	code	of	the	T	cell	receptor	(TCR)	in	patients	who	responded	to	TIL	therapy	was	sequenced	(5).	This	was	done	to	determine	the	specific	melanoma	antigens	that	the	TILs	were	targeting.	Once	the	sequence	was	known,	scientists	engineered	retroviruses	and	lentiviruses	to	include	the	genetic	code	of	the	TCRs	that	were	responsive	towards	tumor	antigens.	In	2005,	these	viruses	were	cultured	with	a	patient’s	own	cells	to	generate	T	cells	with	reactivity	towards	tumor	antigens	in	melanoma	(5).	Initial	responses	were	robust	as	tumor	burden	decreased	substantially,	however,	the	modified	T	cells	also	destroyed	normal	tissue	that	expressed	the	tumor	antigen	(5).	This	became	known	as	the	“on-target	off-tumor”	problem	as	T	cells	killed	cancer	cells	but	also	targeted	normal	tissue	(6).	Moreover,	as	increased	amounts	of	modified	T	cells	were	engineered	to	express	different	tumor	antigens,	a	new	problem	called	the	“off-target	off-tumor”	problem	presented	itself	(6).	In	2013,	two	patients	undergoing	therapy	for	melanoma	with	TCR-modified	T	cells	against	the	MAGE-A3	antigen	died	of	cardiogenic	shock	(7).	Posthumous	analysis	revealed	that	T	cells	had	infiltrated	the	myocardium	and	caused	death	of	cardiomyocytes	(7).	Surprisingly,	the	MAGE-A3	antigen	had	a	similar	structure	to	a	cardiac	protein	known	as	Titin.	This	“off-target	off	–tumor	effect”	occurred	because	the	T	cells	targeting	MAGE-A3	cross-reacted	
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with	the	Titin	receptor,	thereby	causing	destruction	of	cardiac	tissue	(7).	These	TCR-modified	T	cells	are	both	the	precursors	and	modern	partners	of	the	CAR-T	cells.	As	such,	they	have	taught	the	field	of	immunotherapy	much	about	the	risks	that	come	with	engineering	T	cells	to	target	tumor	antigens.	Namely,	the	importance	of	understanding	the	full	range	of	off-target	and	autoimmune	effects	inherent	to	engineered	T	cells.		
Design	of	CAR-T	Cells		 CAR-T	cells	combine	the	binding	properties	of	monoclonal	antibodies	with	the	lytic	function	of	Effector	T	cells.	The	core	structure	of	a	CAR-T	cell	has	stayed	consistent	throughout	the	many	generational	advancements	in	CAR-T	cell	design	(4).	It	is	important	to	recognize	that	the	engineering	of	CAR-T	cells	occurs	through	transduction	of	viral	plasmids	(8).	Significant	effort	is	required	to	generate	plasmids	that	contain	the	specific	genes	that	generate	CAR-T	cells	and	simultaneously	do	not	interfere	with	normal	T	cell	function.	Moreover,	there	exists	a	high	risk	of	gene	insertion	that	may	cause	activation	or	deactivation	of	oncogenes	and	tumor	suppressor	genes,	thereby	leading	to	uninhibited	cell	proliferation	(8).	These	outcomes	have	yet	to	be	seen	in	clinical	trials	but	will	always	exist	due	to	the	inherent	randomness	of	gene	insertion	(8).	Once	transduction	occurs,	T	cells	translate	the	chimeric	antigen	receptor	(CAR).	The	CAR	consists	of	an	extracellular	variable	light	and	heavy	region	(scFv)	derived	from	a	monoclonal	antibody,	a	hinge	
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region,	a	transmembrane	domain,	an	activation	domain,	and	the	TCR	intracellular	signaling	domain	(8)	(Figure	1).	
Figure	1-	Core	structure	of	the	chimeric	antigen	receptor.	Source:	Jensen	at	al.	
	First,	the	scFv	affinity	of	the	ectodomain	predicts	the	binding	affinity	of	the	specific	CAR	(9).	As	such,	the	specific	affinity	of	the	monoclonal	antibody	from	which	the	scFv	is	derived	will	determine	the	ability	of	the	CAR	to	recognize	and	target	cancer	cells.	Many	of	the	scFv	regions	used	in	today’s	CAR-T	cells	are	derived	from	murine	monoclonal	antibodies	and	thus,	include	a	risk	of	rejection	through	anti-idiotype	and	anti-murine	antibodies	derived	from	the	host	(9).	Two	solutions	have	been	proposed	to	this	problem.	First,	researchers	have	increased	efforts	to	determine	the	smallest	amount	of	scFv	ectodomain	necessary	to	induce	immunogenicity	(10).	Second,	scientists	are	in	the	process	of	humanizing	the	scFv		domain	so	as	to	eliminate	the	risk	of	host	rejection	(10).	Both	solutions	hold	promising	directions	for	future	generations	of	CAR-T	cells.	Currently,	however,	the	risk	of	host	rejection	is	still	significant	(10).		
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Implied	in	the	previous	discussion	of	the	scFv	domain	is	the	notion	that	the	CAR-T	cell	does	not	undergo	the	normal	process	of	activation	through	the	APC/MHC	complex	(7).	This	is	another	important	distinction	between	normal	effector	T	cells	and	CAR-T	cells.	Regular	T	cells	funnel	through	a	process	that	leads	to	specific	effector	functions.	First,	antigen	presenting	cells	(APCs)	digest	a	pathogenic.	organism	and	express	a	portion	of	the	pathogen	on	their	MHC	I/II	complex	(7).	Next,	a	T	cell	(CD4	for	MHC	II	and	CD8	for	MHC	I)	binds	to	the	APCs	MHC	complex	with	their	T	cell	receptor	(7).	This	gives	the	T	cell	information	on	the	characteristics	of	the	pathogen	present	in	the	body.	However,	this	does	not	fully	activate	the	T	cell	for	effector	function.	The	second	step	requires	the	APC	to	license	the	T	cell	for	killing.		The	APC	expresses	costimulatory	molecules	(B7	complex)	that	bind	to	receptors	on	the	T	cell	(CD	28)	and	thereby	fully	activate	the	T	cell	for	effector	function	(7).	The	T	cell	would	become	anergic	without	the	second	step	of	costimulatory	activation	
(Figure	2).	The	T	cell	can	now	destroy	pathogens	(Cytotoxic	CD8	T	cell)	or	release	cytokines	that	attract	macrophages,	neutrophils,	and	lymphocytes	to	an	area	of	interest	(Helper	CD4	T	cell)	(7).		CAR-T	cells,	on	the	other	hand,	do	not	require	MHC	activation	as	they	are	directly	activated	when	the	TCR	complex	binds	to	the	target	antigen	(6).	This	type	of	MHC	independent	activation	holds	important	consequences	for	CAR-T	activation	and	killing.	First,	CAR-T	cells	can	be	engineered	to	respond	to	antigens	that	would	not	normally	activate	effector	T	cells	(6).	APCs	do	not	have	the	ability	to	present	numerous	cancer	antigens	and	thus,	cannot	prime	T	cells	for	cancer-specific	killing.	CAR-T	cells,	on	the	other	hand,	do	not	require	MHC	activation	
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and	can	be	engineered	to	target	certain	cancer	antigens	that	are	not	involved	in	APC-MHC	presentation.	Second,	cancer	cells	have	the	ability	to	protect	themselves	from	the	immune	system	by	down-regulating	MHC	complexes	(6).	This	allows	the	tumor	to	evade	the	immune	system	by	prohibiting	T	cell	activation	by	APCs.	CAR-T	cells	circumvent	this	problem	by	binding	directly	to	target	antigens	through	an	APC	independent	manner	(6).	As	such,	the	ability	of	a	tumor	to	down-regulate	MHC	expression	does	not	affect	CAR-T	effector	functions.	However,	the	lack	of	CAR-T	interaction	with	APCs	precludes	the	important	costimulatory	pathway	(B7,	CD28).				
Figure	2-Mechanism	of	T	cell	Activation.	Derived	from	Gotsman	et	al.	
	As	a	consequence,	the	first	generation	of	CAR-T	cells	lacked	full	effector	function	and	quickly	became	anergic	once	activated	by	cancer	antigens	(9).	Researchers	have	partly	remedied	this	problem	by	including	costimulatory	molecules	in	the	TCR	intracellular	signaling	domain	of	the	CAR.	This	aspect	of	CAR-T	function	will	be	more	fully	elaborated	upon	in	the	section	dealing	with	intracellular	
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signaling	of	CAR-T	cells.	As	can	be	elucidated	from	the	above	discussion,	the	lack	of	MHC	activation	in	CAR-T	effector	function	forms	many	of	the	unique	aspects	inherent	to	CAR-T	cells.	Below	the	scFv	region	lies	the	hinge	domain,	which	tethers	the	ectodomain	to	the	plasma	membrane	(8).	The	hinge	domain	influences	the	length	and	elasticity	of	the	CAR	and	thereby	effects	CAR-T	cell	function.	However,	studies	on	hinge	characteristics	have	been	altogether	inconclusive.	For	example,	Hudecek	et	al.	has	shown	that	short	hinges	in	certain	RORI-specific	CARs	increase	effector	function	while	long	hinges	in	CD19-specific	CARs	decrease	effector	function	(10).	The	outcome	of	hinge	length	on	CAR-T	function	has	yet	to	be	standardized	and	most	likely	will	vary	on	which	type	of	antigen	a	specific	CAR-T	recognizes.	As	such,	more	experiments	will	be	required	to	reach	conclusions	regarding	hinge	function.			 The	extracellular	hinge	is	connected	to	the	intracellular	signaling	domain	through	the	transmembrane	domain	(11).	As	such,	the	transmembrane	domain	is	moreso	a	structural	feature	of	the	CAR	rather	than	a	recognition	or	signaling	motif	(11).	Nonetheless,	the	type	of	transmembrane	domain	used	affects	the	stability	and	function	of	the	CAR-T	cell.	First	generation	CAR-T	cells	used	domains	from	CD3-ζ,	CD4,	CD8,	or	CD28	molecules	(11).	Stability	tests	were	performed	on	CARs	made	from	these	varied	receptors.	Results	showed	that	the	CD3-ζ	and	CD28	transmembrane	domains	had	higher	structural	stability	when	compared	to	CD4	and	CD8	molecules	(11).	Subsequent	tests	have	also	shown	that	CD28	molecules	provide	higher	membrane	integrity	compared	to	the	CD3-ζ	(11).	However,	there	is	a	trade	
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off	between	CD28	and	the	CD3-ζ.	CD3-ζ	transmembrane	domains	undergo	a	surprising	and	beneficial	reaction	when	inserted	into	T	cells.	The	CD3-ζ	molecule	dimerizes	with	the	T	cell’s	endogenous	TCR,	which	results	in	increased	effector	function	of	the	resultant	CAR-T	cell	(11).	CD28	domains	do	not	express	this	trait.	Thus,	the	scientist	engineering	the	CAR-T	cell	has	to	weigh	the	options	of	increased	stability	or	increased	effector	function.	Nonetheless,	these	studies	have	shown	that	CAR	transmembrane	domains	can	affect	CAR-T	function	on	a	high	level	and	thus,	have	led	researchers	to	experiment	with	various	transmembrane	domain	structures.			 The	last	motif	of	the	CAR	is	the	endodomain.	The	endodomain	has	undergone	the	most	changes	from	generation	to	generation	due	to	its	central	importance	in	activating	effector	function	in	CAR-T	cells	(12).	The	MHC	independent	activation	of	CAR-T	cells	plays	an	integral	role	in	endodomain	construction.	Namely,	the	lack	of	costimulatory	input	from	the	B7	complex	on	antigen	presenting	cells	precludes	full	activation	of	CAR-T	effector	function.	It	was	previously	stated	that	costimulatory	input	from	APCs	acts	as	a	license	for	T	cells	to	target	pathogenic	organisms	in	the	body.	Without	this	costimulatory	input,	T	cells	become	anergic	and	lie	dormant.	This	intrinsic	mechanism	evolved	to	prohibit	autoimmunity	as	APCs	only	present	their	B7	costimulatory	complex	when	they	have	ingested	a	pathogen.	Without	this	mechanism,	T	cells	would	be	free	to	target	self-antigens	that	APCs	erroneously	ingested.	As	such,	the	presence	of	this	mechanism,	while	protective	against	autoimmunity,	hinders	CAR-T	function.	This	is	due	to	the	ability	of	CAR-T	cells	to	be	
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activated	without	APC	input.	However,	the	lack	of	costimulatory	input	from	an	APC	can	cause	CAR-T	cells	to	become	anergic	after	binding	to	their	target	antigen.	Moreover,	the	tumor	and	tumor	microenvironment	lack	costimulatory	receptors	and	actively	downregulate	mechanisms	that	lead	to	APC-B7	activation.	As	such,	many	first	generation	CAR-T	cells	lacked	efficacy	in	clinical	trials	due	to	hyporesponsiveness	of	CAR-Ts	towards	tumor	antigens	(12).	Further	experimentation	concluded	that	the	lack	of	costimulation	led	to	decreased	efficacy	of	CAR	function	(12).	This	discovery	led	to	a	second	generation	of	CAR-T	cells	that	were	engineered	with	co-stimulatory	endodomains	(12).	For	example,	second	generation	CAR-T	cells	included	CD134/OX40,	4-1BB,	and	CD2	(12).	These	molecules	are	analogous	to	the	intracellular	signaling	events	involved	in	costimulation	of	normal	effector	T	cells	(12).	Third	and	fourth	generation	CAR-Ts	have	included	the	B7	complex	molecules	involved	in	direct	APC	costimulation	(12).	Moreover,	an	added	benefit	of	engineered	endodomains	is	the	ability	of	each	molecule	to	affect	different	downstream	signals.	As	such,	multiple	endodomains	can	be	included	within	a	single	CAR-T	cell	and	thereby,	maximize	the	stimulation	of	a	CAR	when	reacted	against	a	tumor	antigen.	(Figure	3)	However,	the	use	of	multiple	signaling	moieties	increases	the	probability	of	T	cell	exhaustion	(12).	As	a	consequence,	further	research	is	underway	to	engineer	CAR-T	cells	that	are	less	resistant	to	anergy	and	exhaustion	(12).	The	previous	discussion	has	highlighted	the	central	importance	of	endodomain	construction	on	CAR-T	function.	As	techniques	for	CAR	engineering	become	
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increasingly	refined,	specific	endomains	can	be	singled	out	for	certain	cancer	lineages	and	thus,	create	highly	potent	and	targeted	therapies	on	a	patient	specific	basis	(12).			
Figure	3-	Evolution	of	CAR-T	cell	structure.		Derived	from	Maude	et	al.	
	
Clinical	Efficacy	in	Hematological	Malignancies	Second	and	third	generation	CAR-T	cells	have	shown	to	be	extremely	effective	against	certain	types	of	hematological	malignancies.	However,	this	was	not	the	case	with	first	generation	CAR-T	cells.	Initial	trials	with	CAR-T	cells	in	2008	and	2010	resulted	in	disappointing	clinical	outcomes	(13).	Specifically,	two	patients	who	received	CD20	CAR-T	cells	and	four	patients	who	received	CD19	CAR-T	cells	showed	no	cancer	remission	(13).	Analysis	showed	that	the	number	of	CAR-T	cells	in	the	
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body	was	drastically	reduced	after	one	week	of	therapy	(13).	Moreover,	two	patients	developed	antibodies	directed	against	the	CAR	receptor	(13).	This	lack	of	persistence	coupled	with	immune	rejection	led	to	disappointing	clinical	outcomes	in	patients	with	hematological	disorders.	Similar	results	were	also	seen	in	patients	with	solid	tumors.	For	example,	Lamers	et	al.	engineered	first	generation	CAR-T	cells	against	the	CAIX	antigen	present	in	renal	cell	carcinoma	patients	(14).	66%	of	the	patients	developed	hepatitis	due	to	on-target	off-tumor	effects	(14).	The	majority	of	the	patients	also	developed	antibodies	against	the	CAR	receptor	(14).	As	such,	the	CAR-T	imparted	no	clinical	benefit	to	the	patients	(14).	These	negative	results	were	seen	in	many	other	clinical	trials	conducted	with	first	generation	CAR-T	cells.	Due	to	these	failures,	scientists	engineered	second-generation	CAR-T	cells	with	endodomains	that	provided	costimulation	and	increased	activation	of	effector	function	(discussed	above).		 	
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Table	1-	CAR-T	clinical	trials.	Taken	from	Kershaw	et	al.	Abbreviation	of	
relevant	data-CR:	Complete	Remission,	PR:	Partial	Response,	NI:	No	
Information,	SD:	Stable	Disease,	OR:	Objective	Response			The	second-generation	CAR-T	cells	invariably	shifted	the	landscape	of	modern	cancer	therapy	(Table	1).	The	first	trials	of	second	generation	CARs	almost	ubiquitously	involved	patients	with	acute	lymphoblastic	leukemia	(ALL)	and	chronic	lymphoblastic	leukemia	(CLL)	(9).	These	malignancies	were	chosen	due	to	the	CD19	receptor	on	B	cells.	The	CD19	receptor	was	chosen	as	a	target	due	to	its	
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almost	universal	expression	on	cancerous	B	cells	in	ALL	and	CLL	(9).	Moreover,	the	risk	of	on-tumor	off-target	effects	was	minimal,	as	CAR-T	toxicity	towards	healthy	B	cells	did	not	lead	to	dangerous	side	effects	(9).	As	such,	ALL	and	CLL	provided	an	attractive	model	for	initial	clinical	trials	on	second-generation	CAR-T	cells.	Many	of	the	pioneering	trials	were	conducted	at	Memorial	Sloan	Kettering	Cancer	Center	(MSKCC),	University	of	Pennsylvania	(UPenn),	and	the	National	Cancer	Institute	(NCI)	(9).		Initially,	a	small	trial	was	conducted	on	one	patient	in	2011	diagnosed	with	ALL	at	MSKCC	(9).	Treatment	with	CD19	CAR-T	cells	led	to	complete	remission	of	the	patient’s	malignancy.	After	a	two	year	follow-up,	the	cancer	was	still	absent	from	the	patient’s	body	(9).	This	initial	success	led	to	trials	with	larger	cohorts.	Sixteen	patients	at	MSKCC	with	ALL	underwent	treatment	with	CAR-T	cells	in	2012	(15).	Outcomes	indicated	an	88%	cancer	remission	rate	in	the	cohort.	Moreover,	a	phase	1	clinical	trial	at	MSKCC	conducted	with	32	patients	showed	a	91%	complete	remission	rate	(15).	Many	of	these	phase	1	patients	were	treated	with	refractory	disease	(15).	This	disease	type	is	notoriously	hard	to	treat	as	cancer	cells	become	immune	to	classic	chemotherapy	and	radiation	(15).	As	such,	the	remission	rates	seen	in	these	patients	were	unprecedented.	Similar	results	were	seen	in	cases	of	pediatric	ALL	at	UPenn	(15).	Published	results	in	2014	from	this	phase	1	trial	showed	91%	complete	remission	in	a	30	patient	cohort	(15).	These	robust	responses	were	also	seen	at	the	NCI	in	a	cohort	of	children	and	young	adults	(15).	The	CAR-T	cells	used	in	the	three	trials	varied	in	their	CAR	architecture,	and	yet,	similar	results	were	seen	across	all	cohorts.	These	trials	have	demonstrated	the	
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remarkable	effect	of	CAR-T	therapies	on	ALL	and	allude	to	a	functional	cure	in	the	near	future.		 As	previously	stated,	initial	trials	of	second-generation	CAR-T	cells	were	conducted	on	patients	with	CLL.	Compared	to	CAR-T	efficacy	on	ALL,	CLL	showed	less	robust	responses.	In	2011,	six	patients	with	CLL	were	given	CD19	CAR-T	cells	(9).		Results	showed	that	persistence	of	CAR-T	cells	in	the	blood	was	low	in	patients	that	were	not	previously	treated	with	a	lymphodepleting	agent	such	as	Cyclophosphamide	(9).	These	patients	all	had	progressive	disease	after	treatment	with	CAR-T	therapy	(9).	However,	four	patients	pre-treated	with	lymphodepleting	agents	either	had	stable	disease	or	partial	remission	(9).	Another	trial	at	UPenn	showed	similar	results	with	20	out	of	44	patients	achieving	complete	remission	(15).	These	observations	show	that	treatment	of	CLL	with	CAR-T	cells	is	not	as	efficacious	when	compared	to	ALL	due	to	the	lack	of	cell	persistence	in-vivo	(15).	However,	CAR-T	cells	still	provide	a	much	stronger	alternative	to	traditional	chemotherapy	and	will	continue	to	improve	as	more	research	is	done	on	CLL.			
CAR-T	In	Solid	Tumors	Solid	tumors	are	the	most	difficult	of	all	cancer	types	to	be	treated	with	CAR-T	cells.	Even	though	solid	tumors	were	the	first	to	be	treated	with	CAR-T	cells,	no	substantial	clinical	efficacy	has	been	produced	from	many	first,	second,	and	third	generation	CAR-T	cells	(16).	The	challenges	posed	with	solid	tumors	are	numerous	due	to	the	unique	characteristics	of	the	tumor	microenvironment.	Moreover,	
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specific	antigens	unique	to	tumor	cells	are	not	readily	abundant.	This	poses	a	challenge	as	over-expressed	receptors	on	tumors	are	readily	available	on	non-tumor	tissue,	thereby	exacerbating	on-tumor	off-target	effects	(16).	The	same	problem	is	not	seen	in	ALL	and	CLL	since	the	body	can	exist	without	normal	B	cells	for	an	extended	period	of	time	(15).	To	combat	this	problem,	some	scientists	have	engineered	CARs	to	notice	multiple	tumor	antigens	before	activation	of	effector	function	(17).	Scientists	have	also	engineered	inhibitory	CARs	(iCAR)	onto	traditional	CAR-T	cells.	These	iCARs	act	as	termination	signals	if	the	CAR-T	cell	interacts	with	an	antigen	present	on	healthy	tissue	(17).		Another	difference	between	hematological	malignancies	and	solid	tumors	is	the	location	of	the	neoplasia.	In	ALL/CLL,	the	disease	is	blood	borne	so	the	CAR-T	cell	can	act	on	the	cancer	after	direct	intravascular	injection.	In	solid	tumors,	CAR-T	cells	cannot	simply	traffic	to	the	site	of	interest	since	neoplastic	cells	are	located	outside	the	vasculature	(16).	As	such,	the	CAR-T	cells	have	trouble	homing	to	the	tumor	site	and	thereby	cannot	eliminate	the	cancer.	Multiple	partial	solutions	have	been	developed	to	combat	this	problem.	First,	intratumoral	delivery	through	surgical	methods	has	been	shown	to	increase	CAR-T	penetration	and	persistence	(17).	A	surgeon	can	open	the	tumor	to	direct	injection	of	CAR-T	cells	and	thereby,	directly	improve	CAR-T	homing.	This	has	been	shown	to	work	in	clinical	trials	but	cannot	solve	the	problem	of	metastases	(17).	Metastasis	is	the	process	by	which	tumor	cells	disseminate	to	other	organs	within	the	body	(3).	This	is	the	main	cause	of	cancer	mortality	and	is	notoriously	difficult	to	treat	(3).	Surgical	injection	of	CAR-
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T	cells	into	primary	tumor	sites	cannot	solve	the	problem	of	metastasis	since	the	cells	will	be	localized	to	the	primary	tumor.	As	such,	intravenous	injection	of	CAR-T	cells	still	provides	a	more	ideal	means	of	delivery	to	multiple	tumor	sites.	A	clever	solution	has	been	applied	to	partially	solve	this	problem.	Research	on	tumor	biology	has	found	that	cancer	cells	release	chemokines	into	vasculature	at	an	extremely	high	rate	(16).	To	take	advantage	of	this	unique	characteristic,	CAR-T	cells	have	been	engineered	to	express	chemokine	receptors	that	bind	to	specific	chemokines	released	by	a	tumor	(16).	This	would	allow	a	CAR-T	cell	to	traffic	to	the	tumor	site	with	the	aid	of	chemokine	signaling.		Anti-angiogenic	drugs	also	assist	in	CAR-T	trafficking	to	tumor	sites	(18).	Tumors	release	Vascular	Endothelial	Growth	Factor	(VEGF)	to	stimulate	blood	vessel	growth	(18).	This	results	in	tumor	vasculature	that	has	different	properties	compared	to	normal	vasculature.	Namely,	these	vessels	are	immunosuppressive	and	are	not	conducive	towards	T	cell	trafficking	(18).	To	combat	this,	anti-angiogenic	drugs	can	be	used	to	standardize	tumor	vasculature	and	thereby	promote	CAR-T	infiltration	into	tumor	sites	(18).	Trafficking	of	CAR-T	cells	to	tumor	areas	still	does	not	allow	for	full	efficacy	of	effector	function.	The	tumor	microenvironment,	composed	of	cancer	associated	fibroblasts,	pericytes,	extracellular	matrix,	stellate	cells,	immune	cells,	and	endothelial	cells,	creates	both	an	immune	and	physical	barrier	to	CAR-T	activation	and	infiltration	(19).	The	following	paragraphs	will	list	a	specific	negative	aspect	of	
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the	tumor	microenvironment	and	elucidate	mechanisms	by	which	scientists	have	engineered	CAR-T	cells	to	bypass	each	challenge.	
Figure	4-	Components	of	the	tumor	microenvironment.	Derived	from	Joyce	et	
al.										
	 	
	 			First,	tumor	stroma,	composed	of	cancer-associated	fibroblasts	(CAFs),	provides	a	physical	barrier	against	CAR-T	infiltration	(18).	CAFs	also	secrete	extracellular	matrix	proteins	that	sequester	T	cells	away	from	cancer	cells	(18).	
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However,	research	has	shown	that	CAFs	over-express	a	protein	called	Fibroblast	Activating	Protein	(FAP)	(18).	As	a	consequence,	anti-FAP	drugs	used	in	combination	with	CAR-T	cells	have	been	shown	to	control	tumor	growth	(18).	Moreover,	second	generation	CAR-T	cells	have	been	engineered	to	target	the	FAP	protein	on	stromal	cells	(18).	These	studies	have	shown	a	decrease	in	tumor	burden	and	may	be	useful	if	used	with	cancer	specific	CAR-T	cells.		 Second,	the	metabolic	environment	of	the	tumor	microenvironment	is	not	conducive	for	CAR-T	persistence.	Once	neoplasia	has	been	activated,	the	tumor	cell	stops	producing	ATP	through	oxidative	phosphorylation	and	switches	to	aerobic	glycolysis	(19).	As	a	consequence,	the	tumor	environment	becomes	acidic	since	lactic	acid	waste	from	aerobic	glycolysis	lowers	the	pH	of	the	surrounding	area	(19).	This	is	known	as	the	“Warburg	Effect”	as	the	pH	drops	from	7.4	to	6.5	or	less	(19).	Normally,	CAR-T	cells	switch	to	a	glycolytic	state	when	posed	with	sustained	effector	function	(13).	However,	the	acidic	pH	disallows	this	switch	as	the	high	lactic	acid	gradient	stops	membrane	transport	of	lactic	acid	out	of	the	CAR-T	cells	(19).	Thus,	the	CAR-T	cells	cannot	sustain	their	effector	function.	One	solution	to	this	problem	is	to	use	a	proton	pump	inhibitor	to	increase	the	pH	of	the	tumor	microenvironment	and	allow	for	CAR-T	activity	(19).	However,	research	into	metabolic	manipulation	of	the	tumor	microenvironment	is	lacking	and	more	research	still	has	to	be	done	to	increase	CAR-T	efficacy	in	acidic	locations.			 Lastly,	the	tumor	microenvironment	creates	a	state	of	hypoxia	that	further	produces	immunosuppression	(4).	Tumor	cells	produce	a	molecule	named	Hypoxia	
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Inducible	Factor	alpha	(HIF1-alpha)	when	presented	with	a	hypoxic	environment	(4).	HIF1-alpha	acts	to	decrease	CAR-T	function	by	attracting	regulatory	T	cells	(Tregs)	to	a	tumor	site	(18).	Tregs	suppress	the	immune	response	and	will	thereby	restrict	CAR-T	activation.	Hypoxia	also	facilitates	the	release	of	microRNA	from	tumor	cells	that	can	degrade	mRNA	in	CAR-T	cells	(18).	Many	more	examples	of	hypoxia-related	immunosuppression	exist	in	the	tumor	microenvironment	that	will	not	be	covered	in	this	paper.	As	such,	targeting	hypoxia	in	the	microenvironment	can	diminish	the	suppression	of	CAR-T	activity	.	Studies	have	shown	that	simply	having	patients	inhale	high	concentrations	of	oxygen	can	increase	oxygen	content	in	the	tumor	microenvironment	(17).	This	increase	in	oxygen	actually	improves	T	cell	infiltration	and	eventually	decreases	tumor	burden	(17).	The	previous	discussion	has	shown	that	solid	tumors	provide	an	immense	challenge	for	CAR-T	cells.	The	physical	characteristics	of	the	microenvironment	coupled	with	its	immunosuppressive	effects	diminish	both	CAR-T	infiltration	and	effector	function	
(Figure	5).	As	such,	CAR-T	cells	are	being	engineered	to	bypass	or	target	the	tumor	microenvironment	through	both	autonomous	and	combination	therapies.	Nonetheless,	many	more	creative	strategies	will	need	to	be	employed	to	improve	CAR-T	function	in	solid	tumors.			
	 	
	21	
Figure	5-	Mechanism	of	tumor	microenvironment	immuno-suppression.	
Derived	from	Quail	et	al.	
	
Future	of	CAR-T	Therapy		 As	research	into	CAR-T	therapy	has	exploded,	so	has	the	potential	for	combination	immunotherapies.	The	ability	to	combine	CAR-T	therapy	with	checkpoint	inhibitors	(discussed	below)	and	conventional	chemotherapies	holds	promise	towards	higher	tumor	eradication.	The	tumor	microenvironment	presents	infiltrating	T	cells	with	an	immune	blockade	composed	of	PDL1	and	CD80/86	(11).	These	ligands,	expressed	on	tumor	cells	and	tumor	macrophages,	bind	to	PD1	and	CTLA4	receptors	on	T	cells	(11).	As	a	consequence,	T	cells	lose	their	effector	function	and	become	senescent.		Many	promising	studies	and	trials	are	underway	to	test	the	efficacy	of	checkpoint	inhibitors	(PD1	and	CTLA4)	against	various	types	of	cancers.	The	results	from	these	trials	have	been	immensely	promising,	as	tumor	burden	has	drastically	decreased	in	patients	(11).	As	such,	combining	checkpoint	
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blockade	with	CAR-T	cells	would	unleash	the	full	potential	of	modern	immunotherapy.	Checkpoint	blockade,	by	itself,	allows	the	body’s	own	immune	system	to	kill	cancer	cells.	This	would	augment	the	already	powerful	ability	of	CAR-T	cells	to	target	neoplastic	cells	and	thus,	form	a	multiplicative	effect	on	tumor	lysis.			 	A	major	challenge	to	CAR-T	therapy	concerns	cost	and	logistics.	At	the	core	of	the	problem	is	the	necessity	for	CAR-T	cells	to	be	personalized	for	each	patient.	Providing	CAR-T	cells	for	a	patient	requires	cell	collection,	viral	construction,	transduction,	viability	assays,	ex	vivo	cell	proliferation,	and	continuous	clinical	observation.	This	is	no	easy	feat	for	non-academic	institutions	and	small	hospitals.	As	such,	scientists	are	in	the	process	of	developing	“off	the	shelf”	CAR-T	cells	that	can	be	given	to	a	patient	without	personalization	(21).	This	would	greatly	simplify	the	engineering	process	and	thereby	lower	cost	and	increase	access	of	therapy.	However,	the	main	barrier	to	this	is	the	high	probability	of	Graft	Versus	Host	Disease	(GVHD).	GVHD	occurs	when	donor	cells	(graft)	recognize	the	body’s	tissue	(host)	as	foreign	and	proceed	to	attack	host	cells	(Figure	6)	(22).	CAR-T	cells	that	are	not	personalized	would	possess	a	TCR	that	can	recognize	and	target	host	HLA	molecules.	As	such,	“off	the	shelf”	CAR-T	cells	would	have	to	be	engineered	to	reduce	the	possibility	of	GVHD	(21).		
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Figure	6-	Pathogenesis	of	GVHD.	Derived	from	Ferrara	et	al.	
	Many	proposals	are	in	the	process	of	being	tested	but	the	most	promising	includes	using	progenitor	cells	as	the	medium	for	CAR-T	construction	(23).	Progenitor	T	cells	are	not	fully	developed	and	thus,	cannot	discern	the	difference	between	self	and	non-self	antigens	(23).	Therefore,	progenitor	T	cells	cannot	induce	GVHD	due	to	their	inability	to	recognize	HLA	molecules.		As	a	consequence,	they	can	function	as	the	raw	material	for	“off	the	shelf”	CAR-T	cells	as	they	do	not	have	the	potential	to	induce	GVHD	when	given	to	different	hosts	(23).	Once	the	progenitor	CAR-T	is	given	to	the	patient,	the	cells	will	mature	into	normal	effector	T	cells	in	the	thymus	and	develop	standard	T	cell	functions	(23).	Once	fully	matured,	the	progenitor	CAR-T	cells	can	fulfill	their	tumor	targeting	function.	One	study	has	been	
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conducted	on	these	progenitor	CAR-T	cells	with	positive	results	(23).	Induced	pluripotent	stem	T	cells	were	transduced	with	a	CD19	CAR	and	were	given	to	mice	implanted	with	human	cancer	cells	(xenograft)	(23).	Results	showed	that	these	progenitor	CAR-T	cells	were	able	to	effectively	target	CD19	expressing	cancer	cells	(23).	This	type	of	CAR-T	cell	holds	promise	for	a	future	where	CAR-T	cells	can	be	safe,	highly	effective,	and	affordable	to	all	patient	populations.	This	is	only	one	example	of	the	promise	CAR-T	cells	hold	for	the	future	of	cancer	treatment.	As	with	any	new	therapy,	caution	must	be	taken	to	validate	trials	and	understand	significant	side	effects.	A	deliberate	and	rigorous	method	must	be	implemented	to	mitigate	the	hysteria	that	comes	with	such	powerful	technology.	Nonetheless,	the	future	of	medicine	has	been	unequivocally	changed	by	the	introduction	of	these	chimeric	antigen	receptor	T	cells	to	the	widening	medical	landscape.		
Immune	Checkpoints	At	the	core	of	modern	immunotherapy	is	the	T	cell.	This	fraction	of	the	immune	system	holds	the	immense	responsibility	of	carrying	a	large	proportion	of	the	cytotoxic	functions	of	the	body.	Thus,	the	T	cell	holds	an	enormous	amount	of	power	when	a	patient	develops	a	tumor.	Either	the	T	cell	can	target	the	tumor	or	it	can	stay	quiet	and	let	the	tumor	breed.	As	such,	the	tumor	goes	to	immense	lengths	to	disrupt	the	T	cell	from	targeting	neoplastic	cells.	The	tumor	hides	itself	behind	a	wall	of	stroma	and	extracellular	matrix.	It	cloaks	itself	under	the	guise	of	normal	tissue	by	under	expressing	activation	markers.	It	disseminates	throughout	the	body	
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looking	for	fertile	soil	where	it	can	create	anew.		And	lastly,	it	forces	the	body’s	own	troops	to	become	lethargic	and	exhausted	(Figure	7)	(4).	Every	point	in	this	multi-pronged	attack	by	the	tumor	is	being	targeted	by	modern	cancer	therapies.	Antibodies	against	tumor	stroma	and	extracellular	matrix	proteins	have	been	developed	to	disrupt	the	tumor	microenvironment.	Molecular	libraries	are	being	probed	to	determine	neo-antigen	expression	on	cancer	cells.	Anti-angiogenic	drugs	stop	formation	of	blood	vessels	that	allow	for	metastasis.	Lastly,	checkpoint	inhibitors	combat	the	ability	of	tumors	to	induce	T	cell	exhaustion.	This	last	point	is	where	modern	developments	in	immunotherapy	come	into	play.	
Figure	7-	Cancer	cells	adapt	to	their	environment	and	proliferate	by	
developing	a	combination	of	these	hallmarks.	Derived	from	Weinberg	et	al.	
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The	immune	system	has	evolved	multiple	degenerate	mechanisms	to	preclude	the	possibility	of	auto-immunity.	This	manifests	itself	in	the	form	of	immune	checkpoints	(24).	Immune	checkpoints	decrease	the	probability	of	auto-immune	disease	and	shield	normal	tissue	from	damage	during	immune	activation	(24).	However,	there	is	a	delicate	balance	between	immune	tolerance	and	immune	activation.	This	is	elegantly	exposed	in	the	case	of	the	T	cell.	The	T	cell	receptor	recognizes	a	foreign	antigen	and	undergoes	a	process	where	numerous	downstream	effectors	are	activated	(ZAP70,	FYN,	LCK,	LAT	etc)	(25).	The	quality	and	quantity	of	downstream	activation	is	based	upon	the	input	the	T	cell	receives	from	costimulatory	and	inhibitor	molecules.	These	signals	are	normally	located	on	antigen	presenting	cells	(monocytes,	macrophages,	dendritic	cells),	B	cells,	NK	cells,	and	normal	tissue	(24).	However,	in	the	case	of	neoplasia,	cancer	cells	hijack	the	system	for	their	own	ends.	This	is	manifested	in	the	expression	of	markers	that	induce	T	cell	exhaustion	(25).	Receptors	and	ligands	for	T	cell	activation	are	normally	not	over-expressed	in	cancer	relative	to	normal	tissue	(25).	Inhibitory	receptors	towards	T	cell	activation,	on	the	other	hand,	are	highly	expressed	on	both	cancer	cells	and	supporting	cells	in	the	tumor	microenvironment	(25).	This	discovery	has	allowed	scientists	to	develop	antibody	therapies	that	reduce	on-tumor	off-target	effects.	Most	of	the	conventional	therapies	used	in	cancer	target	the	cancer	cells	themselves	and	thereby	circuitously	boost	the	immune	system’s	ability	to	target	neoplastic	cells.	However,	in	the	case	of	checkpoint	blockade,	modern	therapies	target	the	receptors	and	ligands	on	the	T	cell	rather	than	the	tumor	(24).	
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This	directly	activates	the	immune	system	and	allows	it	to	kill	cancer	cells	in	a	safe	and	targeted	manner,	without	conventional	side	effects.	CTLA4	will	be	used	as	an	example	to	illustrate	this	concept.		Cytotoxic	T	Lymphocyte	Associated	Protein	4	(CTLA4)	was	the	first	inhibitory	receptor	to	be	identified	and	targeted	(26).	It	is	primarily	located	on	T	cells	and	is	involved	in	inhibition	of	effector	function	(26).	It	does	this	through	inhibiting	co-stimulatory	activation	by	CD28.	As	previously	discussed,	antigen	presenting	cells	(APCs)	license	a	T	cell	to	kill	by	providing	costimulatory	input	through	the	B7	complex.	The	B7	complex,	composed	of	CD80	and	CD86,	binds	to	the	CD28	receptor	on	T	cells	and	allows	the	cell	to	carry	out	its	effector	function.	This	only	occurs	once	the	T	cell	has	been	presented	with	a	pathogenic	antigen	by	an	APC.	CTLA4	is	inhibitory	because	it	competes	with	the	normal	costimulatory	pathway	(27).	It	binds	to	CD80	and	CD86	and	thereby	disallows	CD28	interaction	with	the	B7	complex	(27).	This	occurs	because	CTLA4	has	a	higher	affinity	for	the	B7	complex	compared	to	CD28	(27).	CTLA4	expression	also	directly	inhibits	T	cells	function	by	catalyzing	an	inhibitory	cascade	within	the	T	cell	(27).	As	such,	CTLA4	has	a	dual	inhibitory	role.	It	insulates	CD28	from	the	B7	complex	and	directly	inhibits	T	cells	activity	through	intracellular	signaling	pathways	(27).	CTLA4	plays	an	integral	role	in	the	body’s	ability	to	stop	autoimmune	events.	This	is	exemplified	in	knockout	studies	where	the	gene	for	CTLA4	(Ctla4)	is	removed	from	a	mouse’s	genome	(26).	In	these	cases,	the	mouse	experiences	an	immense	hyper-activation	of	its	immune	system	which	eventually	leads	to	death	(26).	Interestingly,	CTLA4	is	moreso	a	factor	
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in	CD4	helper	T	cells	and	Tregs	than	in	CD8	cytotoxic	T	cells	(28).	CD4	T	cells	recognize	MHC	II	antigens	on	APCs	and	release	cytokines	that	mediate	B	cell	and	CD8	T	cell	activation	(28).	Tregs	are	a	subset	of	CD4	cells	that	inhibits	immune	function	(28).	CTLA4	expression	on	helper	T	cells	suppresses	their	ability	to	activate	the	immune	system	through	the	dual	inhibitory	mechanism	previously	discussed.	The	mechanism	by	which	CTLA4	activates	Tregs	is	currently	unknown	(28).	This	paradoxical	function	illustrates	the	complexity	of	the	immune	system’s	response	to	a	certain	signal.	One	signal	can	activate	a	certain	pathway	in	a	cell	but	inhibit	the	same	pathway	in	a	different	cell.	However,	when	seen	from	a	higher	vantage	point,	CTLA4	expression	leads	to	overall	immunosuppression	by	inhibiting	CD4	T	cells	and	activating	Tregs	(28).	Thus,	it	follows	that	blocking	CTLA4	through	an	antibody	would	unleash	CD4	activity	and	reverse	Treg	suppression	(Figure	8).	This	is	precisely	what	happened	in	clinical	trials	involving	CTLA4	blocking	antibodies	(29).	Initially	CTLA4	as	a	single	agent	did	not	prove	successful	as	tumor	burden	was	not	drastically	reduced	(29).	However,	a	small	subset	of	patients	reacted	very	positively	to	the	treatment	(29).	These	patients	had	tumors	that	were	immunogenic.	Immunogenic	tumors	are	characterized	by	lymphocyte	infiltration	and	general	immune	activation	in	the	tumor	area	(29).	CTLA4	only	decreased	tumor	burden	in	patients	that	already	had	an	endogenous	tumor	response	(29).	This	observation	follows	closely	in	line	with	our	previous	discussion.	CTLA4	inhibits	CD4	activation	and	boosts	Treg	suppression.	As	such,	CTLA4	blockade	would	only	work	in	instances	where	CD4	cells	and	Tregs	are	already	present	in	tumor	areas.	Since	it		
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Figure	8-	Mechanism	of	T-cell	inactivation	by	CTLA4	and	corresponding	CTLA4	
inhibition	by	Ipilimumab.	Derived	from	Gardner	et	al.	
	cannot	activate	immune	infiltration,	it	cannot	work	in	tumors	that	are	non-immunogenic.	Thus,	CTLA4	can	only	boost	an	ongoing	immune	response	(29).	These	studies	led	to	the	development	of	clinical	CTLA4	inhibitory	antibodies	by	pharmaceutical	companies.	Bristol-Myers	Squibb	eventually	won	the	race	and	released	the	FDA	approved	ipilimumab	(Trade	name	Yervoy)	in	2010	for	the	treatment	of	melanoma	(25).	This	date	is	significant	as	it	represents	the	first	FDA	drug	approved	for	use	in	checkpoint	blockade	(25).	In	general,	CTLA4	blockade	did	not	live	up	to	its	initial	expectations	due	to	the	lack	of	pronounced	tumor	regression	and	unpronounced	objective	clinical	response	(25).	However,	Ipilimumab	has	gone	on	to	be	used	in	combination	with	conventional	chemotherapy	regimens	with	moderate	success	(25).	This	initial	foray	into	checkpoint	blockade	paved	the	way	for	
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therapies	targeting	the	PD1/PDL1	axis.		Programmed	Cell	Death	Protein	1	(PD1)	was	first	cloned	and	isolated	in	1992	(30).	There	are	two	ligands	that	activate	PD1:	PDL1	and	PDL2.	PD1	is	mainly	expressed	on	mature	T	cells	located	in	peripheral	tissue	(30).	This	contrasts	to	CTLA4,	which	is	expressed	on	naïve	T	cells	after	antigen	presentation	by	an	APC	(26).	This	is	an	important	distinction	and	one	that	will	further	an	understanding	of	PD1	blockade’s	higher	clinical	efficacy	when	compared	to	CTLA4.	PD1	regulates	T	cell	activity	within	tumor	tissue	while	CTLA4	is	involved	in	initial	T	cell	activation	(27).	CTLA4	is	up-regulated	in	naïve	or	resting	T	cells	at	the	time	of	antigen	presentation	(27).	More	specifically,	CTLA4	inhibits	continuous	activation	of	immature	T	cells	by	sequestering	the	CD28	costimulatory	molecule	away	from	an	APC’s	B7	complex	(27).	This	inhibits	continuous	activation	of	effector	function	and	allows	the	T	cell	to	target	one	antigen	at	a	time.	CTLA4	is	expressed	once	the	T	cell	receptor	has	been	activated	(27).	CTLA4	expression	increases	with	stronger	TCR	activation	(27).	PD1,	on	the	other	hand,	is	not	involved	in	initial	T	cell	activation	by	an	APC	(30).	Rather,	it	responds	to	global	levels	of	inflammation	(30).	This	can	be	illustrated	with	Interferon	gamma.	Interferon	gamma	is	a	cytokine	released	by	T	helper	1	cells	during	inflammatory	events	in	peripheral	tissue	(30).	As	such,	interferon	gamma	interaction	with	a	T	cell	induces	the	expression	of	PD1	(30).	This	contrasts	to	CTLA4,	where	APC	interaction	with	a	naïve	T	cell	induced	expression	of	CTLA4	(27).	The	CTLA4	pathway	allows	for	a	consistent	level	of	T	cell	activation	in	the	presence	of	ligands	with	varying	affinities	(27).	The	PD1	pathway	decreases	T	
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cell	function	in	response	to	heavy	and	chronic	inflammation	(30).	Thus,	PD1	upregulation	occurs	in	response	to	global	levels	of	inflammation	in	peripheral	tissue	while	CTLA4	activation	mediates	T	cell	activation	in	non-peripheral	tissue.	Moreover,	PD1	is	expressed	on	a	greater	variety	of	cells	when	compared	to	CTLA4	(27).	CTLA4	is	expressed	almost	exclusively	on	naïve	or	dormant	T	cells	(26).	PD1,	on	the	other	hand,	it	present	on	T	cells,	B	cell,	NK	cell,	and	some	myeloid	populations	(31).	This	also	accounts	for	the	higher	efficacy	of	PD1	blockade	as	PD1	blocking	antibodies	might	also	unleash	NK	cell	and	B	cell	activity	in	tumor	sites	(31).		Activation	of	PD1	induces	exhaustion	and	anergy	in	T	cells	(31).	As	such,	it	plays	an	important	role	in	mitigating	the	tissue	damage	that	comes	with	chronic	infection	(31).	This	mechanism	evolved	to	protect	the	body	from	unnecessary	tissue	damage	during	inflammatory	states.	However,	cancer,	once	again,	hijacks	this	autoimmune	mechanism	for	its	own	survival.	In	this	case,	cancer	cells	upregulate	PD1	ligands	(PDL1	and	PDL2)	that	bind	to	and	immobilize	tumor	infiltrating	T	cells	(TILs)	(31).	PDL1	is	the	major	PD1	ligand	used	by	cancer	cells.	Moreover,	it	is	also	expressed	on	myeloid	cells	(macrophages	and	dendritic	cells),	fibroblasts,	and	other	components	of	the	tumor	microenvironment	(31).	PDL2	is	also	expressed	on	tumor	cells	in	B	cell	lymphomas	and	Hodgkin’s	disease	(31).	However,	PDL2	does	not	play	as	significant	a	role	in	patient	survival	as	PDL1	(31).	Many	studies	have	shown	that	the	expression	of	PDL1	in	patients	with	cancer	results	in	a	poorer	prognosis	when	compared	to	patients	without	PDL1	expressing	tumors	(31).	This	observation	agrees	firmly	with	the	mechanism	of	PD1	exhaustion	previously	discussed.	As	such,	
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the	question	arises:	How	is	PDL1	upregulated	by	tumors?	Two	theories	have	been	developed	to	address	this	question	(Figure	9).			
Figure	9-	Competing	mechanisms	of	PDL1	upregulation.	Derived	from	Pardoll	
et	al.	
	The	first	theory	uses	an	internal	genetic	approach	to	the	T	cell.	Cells	become	neoplastic	due	to	the	activation	of	proto-oncogenes	or	deactivation	of	tumor	suppressor	genes	(32).	These	mutations	cause	changes	in	intracellular	signaling	pathways	that	eventually	lead	to	uncontrolled	cell	proliferation.	Thus,	at	its	core,	cancer	is	a	genetic	disease	(4).	The	expression	of	PDL1	might	also	follow	this	pathway	of	abnormal	expression.	This	theory,	termed	“innate	immune	resistance,”	proposes	that	internal	oncolytic	driver	mutations	eventually	result	in	upregulation	of	PDL1	on	cancer	cells	(32).	In	glioblastomas,	the	continuous	internal	oncolytic	stimulation	causes	deletion	of	the	PTEN	gene	(32).	The	lack	of	PTEN	unleashes	the	
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PI3K-AKT	pathway,	which	leads	to	uncontrolled	cell	proliferation	and	PDL1	expression	(32).	The	same	goes	for	patients	with	lymphoma	and	lung	cancer.	The	deletion	of	a	certain	gene	leads	to	continuous	activation	of	the	ALK-STAT3	pathway,	which	causes	expression	of	PDL1	(32).	The	idea	behind	the	“innate	immune	resistance”	theory	looks	at	cancer	cells	in	a	vacuum.	Meaning,	the	expression	of	checkpoint	molecules	will	undoubtedly	occur	after	a	certain	amount	of	oncolytic	mutations.	This	theory	does	not	take	into	account	the	mechanisms	by	which	cancer	cells	interact	with	non-cancerous	immune	components.		The	second	theory	of	PDL1	upregulation,	named	“adaptive	immune	resistance,”	involves	both	the	cancerous	and	non-cancerous	cells	(32).	It	takes	into	account	the	inflammatory	conditions	present	in	the	tumor	microenvironment.	Cancer	has	classically	been	called	“the	wound	that	never	heals”	due	to	the	observations	that	tumor	progression	exhibits	similar	characteristics	to	the	process	of	wound	healing	(33).	These	similarities	include	growth	of	new	blood	vessels	(angiogenesis),	the	shifting	of	the	extracellular	matrix	around	stromal	cells,	changes	in	cell	adhesion,	upregulation	of	specific	genes,	and	inflammatory	cytokine	signaling	(33).	In	the	case	of	a	wound,	the	body	terminates	the	immune	reaction	after	wound	closure	and	pathogen	removal	(33).	However,	in	cancer,	the	immune	activation	continues	endlessly	due	to	progressive	actions	by	the	tumor	(33).	The	theory	of	“adaptive	immune	resistance”	follows	from	this	notion.	PDL1	on	cancer	cells	has	shown	to	be	upregulated	in	response	to	actions	by	the	immune	system	(32).	Normally,	cells	express	PDL1	during	times	of	chronic	inflammation	and	infection	
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(32).	This	stops	T	cells	from	destroying	tissue	located	peripheral	to	the	site	of	infection.	Cells	know	to	express	PDL1	when	approached	by	inflammatory	cytokines.	In	most	cases,	the	inflammatory	cytokine	is	interferon	gamma	(32).	The	T	cell	releases	interferon	gamma,	which	interacts	with	STAT3	in	unwounded	tissue	(32).	This	eventually	leads	to	upregulation	of	PDL1	on	normal	tissue,	which	then	stops	the	T	cell	from	releasing	interferon	gamma	(32).	The	negative	feedback	mechanism	is	important	for	combating	continuous	T	cell	activation.		In	cancer,	the	same	defense	mechanism	occurs	due	to	T	cell	infiltration	into	tumor	sites.	However,	in	this	case,	the	release	of	interferon	gamma	does	not	induce	a	brief	increase	in	PDL1	expression	(32).	Rather,	the	tumor	hijacks	the	transient	upregulation	for	its	own	ends	and	expresses	PDL1	in	a	constitutive	fashion	(32).	This	theory	is	supported	by	observations	concerning	tumor	infiltration	and	variability	in	PDL1	expression	on	different	areas	within	a	tumor	(32).	Studies	on	PDL1	expression	in	melanoma	have	shown	that	PDL1	expression	is	not	homogenous	within	a	single	tumor	(32).	Rather,	PDL1	is	upregulated	only	in	areas	of	lymphocytic	infiltration	(32).	This	supports	the	“adaptive”	theory	as	immune	infiltration	is	a	pre-requisite	for	PDL1	expression.	The	infiltrating	T	cells	release	interferon	gamma	that	upregulates	PDL1	on	cancer	cells	permanently.	It	follows	that	PDL1	should	not	be	expressed	in	areas	that	lack	lymphocytic	infiltration	due	to	the	absence	of	inflammatory	cytokines.	This	is	precisely	what	is	observed	(32).	As	such,	the	“adaptive	immune	resistance”	more	fully	encompasses	the	complexity	inherent	in	the	tumor	microenvironment	while	simultaneously	accounting	for	clinical	observations	concerning	non-uniform	PDL1	
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expression	in	tumors.	Implicit	in	this	discussion	is	the	notion	that	both	immune	and	non-immune	cells	contain	the	ability	to	express	PDL1	(31).	Any	tissue	stimulated	by	interferon	gamma	will	express	PDL1	to	mitigate	the	damage	caused	by	T	cells	during	inflammation	(31).	This	contrasts	with	PD1,	which	is	mainly	expressed	on	T	cells	(31).	As	such,	the	potential	for	ubiquitous	expression	of	PDL1	holds	the	key	to	understanding	the	discrepancy	of	safety	profiles	between	PD1	and	PDL1	inhibitors.		Therapies	composed	of	PDL1	inhibition	lead	to	higher	incidences	of	side	effects	and	autoimmune	events	(34).	This	observation	follows	from	the	notion	that	PDL1	can	be	expressed	on	many	cell	types	(30).	PDL1	is	critical	for	the	maintenance	of	an	immunosuppressive	environment	during	inflammation	(30).	Providing	PDL1	inhibition	for	a	patient	deactivates	mechanisms	of	systemic	immuno-suppression.	This	increases	the	potential	for	inflammatory	damage	at	sites	peripheral	to	the	tumor	(30).	PD1	inhibition,	on	the	other	hand,	mainly	affects	T	cells	and	thus,	does	not	predispose	the	body	to	unwanted	autoimmune	events.	As	a	consequence,	PD1	blockade	has	been	more	efficacious	when	compared	to	PDL1	due	to	the	lower	incidence	of	side	effects	and	greater	specificity	of	immune	cell	targeting	(34).	This	will	be	more	fully	elaborated	on	in	the	following	discussion	concerning	clinical	trials	of	PD1	and	PDL1	blockade.		
Clinical	Trials	of	PD1/PDL1	Blockade	As	can	be	seen	from	the	previous	discussion,	the	PD1	and	PDL1	axis	is	implicated	in	the	inability	of	the	immune	system	to	target	cancer	cells.	The	binding	
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of	PDL1	to	PD1	leads	to	exhaustion	in	tumor	infiltrating	lymphocytes	and	thereby	allows	unabated	growth	of	tumors.	As	such,	disrupting	the	PD1/PDL1	axis	carries	great	potential	in	unleashing	the	immune	system	upon	cancerous	cells	(Figure	6).	This	method	of	cancer	therapy	has	a	much	lower	risk	of	adverse	side	effects	when	compared	to	conventional	chemotherapy	and	radiation.	Chemotherapy	and	radiation	simultaneously	target	tumors	and	all	highly	proliferative	cells	(35).	Hair	follicles,	epidermal/dermal	cells,	and	various	gastrointestinal	cells	are	susceptible	to	damage	by	conventional	therapies	due	to	their	highly	proliferative	nature	(35).	As	such,	side	effects	like	hair	loss,	skin	disorders,	fatigue,	and	nausea	are	a	function	of	the	non-targeted	mechanism	by	which	conventional	cancer	therapies	rid	the	body	of	neoplastic	cells	(35).		PD1/PDL1	blockade,	on	the	other	hand,	would	only	target	cells	that	express	these	specific	receptors.	The	majority	of	PD1	in	the	body	is	expressed	on	a	specific	subset	of	mature	T	cells	and	thus,	the	potential	for	off-target	interactions	are	significantly	diminished	(30).	This	notion	has	been	manifested	in	the	formation	of	small	molecule	inhibitors	against	PD1	and	PDL1.	Several	PD1	inhibitors	have	been	approved	for	use	in	specific	types	of	cancers.	The	following	discussion	will	expand	upon	the	clinical	efficacy	of	FDA	approved	PD1/PDL1	blockade	in	melanoma	and	non-small	cell	lung	cancer	(NSCLC).	
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Figure	10-	Mechanism	of	PD1	blockade.	Derived	from	Armand	et	al.	
	 Malignant	melanoma	is	the	fifth	most	prevalent	cancer	in	the	United	States	and	the	past	thirty	years	has	seen	a	growing	incidence	of	melanoma	in	the	American	population	(36).	Approximately,	132,000	new	cases	of	melanoma	are	diagnosed	every	year	across	all	countries	(36).	In	the	United	States,	roughly	10,000	individuals	will	succumb	to	the	disease	in	2016	(36).	Nonetheless,	melanoma	is	known	to	be	a	relatively	curable	disease	when	diagnosed	in	early	stages.	91%	of	patients	with	localized	melanoma	survive	for	five	years	after	initial	diagnosis	(36).	However,	this	rate	drops	once	melanoma	approaches	higher	stages	of	dispersion.	16%	of	patients	survive	once	melanoma	has	progressed	to	distant	sites	and	metastasis	(36).	This	is	where	checkpoint	blockade	comes	into	play.	More	specifically,	the	anti-PD1	inhibiting	antibodies,	nivolumab	and	pembrolizumab,	have	shown	to	be	highly	
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efficacious	in	the	treatment	of	advanced	melanoma.			 Nivolumab,	a	human	monoclonal	antibody	targeting	PD1,	was	approved	by	the	FDA	on	December	14,	2014	for	treatment	of	unresectable	(immune	to	surgery)	and	metastatic	melanoma	(37).	The	first	phase	II	trial	on	nivolumab	was	carried	out	with	a	cohort	of	418	patients	diagnosed	with	unresectable	and	malignant	melanoma.	25%	of	participants	treated	with	nivolumab	exhibited	partial	tumor	response	(37).	Median	objective	survival	of	patients	after	one	year	was	73%.	This	was	a	drastic	improvement	in	response	when	compared	to	the	42%	objective	survival	in	the	standard	chemotherapy	group	(dacarbazine)	(37).	Moreover,	the	safety	profile	of	nivolumab	was	much	higher	than	that	of	standard	chemotherapy.	11%	of	patients	in	the	nivolumab	group	exhibited	significant	side	effects	compared	to	the	18%	in	the	chemotherapy	regimen	(37).	Another	study	using	nivolumab	and	ipilimumab	(CTLA4	inhibitory)	showed	the	power	of	combining	PD1	blockade	with	classic	immunotherapy	(38).	The	study,	composed	of	86	patients,	showed	that	the	combination	of	nivolumab	and	ipilimumab	led	to	a	40%	objective	response	rate	while	the	monotherapy	group	exhibited	a	20%	objective	response	(38).	As	such,	the	combination	therapy	resulted	in	a	higher	response	rate	and	higher	median	one-year	survival	when	compared	to	monotherapy	(38).	These	results	are	drastic	improvements	over	conventional	therapy	and	have	allowed	PD1	blockade	to	become	a	first	line	therapy	in	the	treatment	of	advanced	melanoma	(38).				 Pembrolizumab	is	another	humanized	monoclonal	antibody	targeting	the	PD1	receptor	(39).	The	efficacy	of	pembrolizumab	was	established	in	a	phase	I	study	
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composed	of	135	patients	(39).	The	patients	were	divided	into	three	cohorts	(39).	The	first	cohort	received	10mg/kg	every	two	weeks,	the	second	10mg/kg	every	three	weeks,	and	third	2mg/kg	every	two	weeks	(39).	Overall	response	rate	was	38%	across	all	three	cohorts	(39).	However,	results	showed	that	patients	given	10mg/kg	of	pembrolizumab	every	two	weeks	exhibited	a	52%	response	rate	(39).	Moreover,	these	patients	had	a	progression	free	survival	of	seven	months	(39).	This	study	laid	the	foundation	for	pembrolizumab’s	remarkable	efficacy	in	advanced	melanoma	and	facilitated	its	designation	as	an	FDA	“fast	track”	drug	(39).	Another	phase	one	trial	conducted	on	173	patients	with	refractory	melanoma	showed	similar	results	(39).	Refractory	melanoma	is	more	difficult	to	treat	due	to	the	adaptive	mechanisms	that	the	tumor	employs	to	bypass	the	immune	system	(39).	This	trial	contained	two	cohorts	(39).	The	first	was	administered	2mg/kg	every	three	weeks	while	the	second	was	given	10	mg/kg	every	three	weeks	(39).	The	overall	response	rate	was	26%	while	the	progression	free	survival	for	the	2mg/kg	and	10mg/kg	groups	were	22	weeks	and	14	weeks	respectively	(39).	These	results	coupled	with	low	amounts	of	adverse	events	allowed	pembrolizumab	to	be	approved	by	the	FDA	for	use	in	melanoma	patients	on	September	4,	2014	(39).				 Trials	on	PDL1	targeting	antibodies	have	achieved	similar	or	slightly	lower	response	rates	when	compared	to	PD1	antibodies	(37).	However,	the	toxicities	of	these	drugs	have	been	a	cause	of	concern.	For	example,	MSB0010718C,	a	humanized	monoclonal	antibody	targeting	PDL1,	is	currently	being	tested	for	safety,	tolerability,	and	pharmacokinetics	in	a	phase	I	study	(40).	27	patients	with	solid	
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tumors	were	chosen	for	the	trial	(40).	Two	patients	had	to	discontinue	treatment	due	to	adverse	events	while	three	patients	developed	grade	three	to	four	adverse	events	(40).	These	toxicities	are	much	higher	than	those	seen	in	PD1	patients.	The	rationale	for	this	discrepancy	involves	the	high	expression	levels	of	PDL1	in	non-immune	tissue	(previously	discussed).		Nonetheless,	the	use	of	anti-PDL1	antibodies	still	shows	promise	as	an	immunotherapy	and	further	research	is	ongoing	to	both	reduce	toxicity	and	enhance	its	tumor	targeting	ability.	Treatment	of	melanoma	with	anti-PD1	and	PDL1	antibodies	has	proven	to	be	successful	in	patients	with	unresectable	and	advanced	stages	of	the	disease	(39–40).	These	melanoma	trials	facilitated	the	FDA	approval	of	nivolumab	and	pembrolizumab.	Consequently,	this	has	laid	the	foundation	for	the	usage	of	these	antibodies	in	a	greater	variety	of	cancer	types.	Most	recently,	this	has	expanded	into	trials	on	patients	with	lung	cancer.		 Non-small	cell	lung	cancer	(NSLC)	accounts	for	the	plurality	of	cancer	deaths	worldwide	(41).	Most	patients	are	diagnosed	at	advanced	disease	progression	and	metastasis	(41).	These	patients	have	eight	to	ten	months	of	survival	after	diagnosis,	which	is	low	compared	to	the	large	majority	of	cancers	(41).	Median	overall	survival	increases	in	individuals	with	specific	driver	mutations	as	targeted	therapies	have	been	developed	to	treat	these	actionable	patients	(41).	However,	only	25%	of	cases	contain	these	mutations	and	thus,	the	majority	of	patients	are	treated	with	conventional	chemotherapy	and	platinum-based	medicine	(41).	As	such,	novel	therapies	are	in	the	process	of	being	tested	on	individuals	with	NSCLC.	The	most	
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promising	has	been	PD1	blockade.	A	phase	one	trial	conducted	with	nivolumab	on	129	patients	with	NSCLC	showed	a	17%	overall	survival	rate	(42).	This	result	is	especially	noteworthy	in	that	54%	of	participants	were	thrice	treated	with	conventional	therapies	(42).	Moreover,	these	responses	were	stable	with	median	response	durations	of	seventeen	months.	Trials	with	pembrolizumab	have	shown	similar	robust	responses.	In	a	phase	one	trial,	495	patients	with	advanced	or	metastatic	NSCLC	given	pembrolizumab	produced	a	response	rate	of	19.4%	(42).	This	trial	also	contained	individuals	who	previously	underwent	at	least	three	regimens	of	chemotherapy	(42).	Treatment	with	pembrolizumab	was	well	tolerated	by	patients.	Only	9.5%	of	patients	exhibited	adverse	events	with	one	treatment	related	death	(42).	Moreover,	trials	have	been	conducted	comparing	PD1	blockade	with	conventional	second	line	therapy	(docetaxel)	(42).	Patients	given	nivolumab	responded	with	a	median	overall	survival	of	nice	months	compared	to	docetaxel’s	six	months	(42).	One-year	survival	with	nivolumab	was	42%	compared	to	24%	with	docetaxel	(42).	These	robust	responses	have	elevated	PD1	blockade’s	status	to	that	of	the	primary	second-line	therapy	in	NSCLC	(Table	2)	(31).		
	42	
	
Table	2-	Summary	of	clinical	trials	targeting	PD1.	Derived	from	Nguyen	et	al	
	
Conclusion	Cancer	has	become	the	prime	medical	challenge	of	the	modern	era.	The	conventional	therapies	for	cancer	do	not	provide	the	means	to	effectively	tackle	this	problem	due	to	their	non-targeted	and	toxic	approach	to	tumor	killing.	As	such,	the	modern	field	of	immunotherapy	has	brought	upon	a	revolution	in	the	establishment’s	approach	to	cancer	treatment.	CAR-T	cells	provide	the	means	to	
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target	specific	cancer	antigens	by	engineering	a	patient’s	endogenous	immune	cells.	Moreover,	CAR-T	cells	have	been	shown	to	be	safe	in	clinical	settings.	They	have	been	proven	to	be	efficacious	in	hematological	malignances	and	are	currently	being	engineered	for	use	in	solid	tumors.	Checkpoint	blockade	has	also	been	used	to	tremendous	effect.	Basic	research	on	immune	regulation	has	led	to	the	development	of	therapies	that	can	negate	the	suppressive	effects	of	the	tumor	microenvironment.	PD1	inhibitors	have	been	shown	to	be	effective	in	patients	with	advanced	melanoma	and	non-small	cell	lung	cancer.	Moreover,	trials	are	currently	underway	to	broaden	the	scope	of	checkpoint	blockade	to	other	cancer	types.	The	next	decade	will	see	the	manifestation	of	these	discoveries	in	the	wider	populace.	However,	such	powerful	technology	does	not	come	without	a	price.	The	current	transition	brings	about	many	important	questions	regarding	the	economics	and	logistics	of	medical	treatment.	How	much	do	these	therapies	cost?	Who	will	be	able	to	afford	them?	How	will	current	policy	changes	within	the	medical	system	affect	the	production	and	usage	of	these	treatments?	These	questions	cannot	be	comprehensively	answered	with	current	information.	As	such,	policy	makers,	pharmaceutical	companies,	and	physicians	must	be	diligent	and	cautious	in	their	approach	to	such	powerful	technology.	The	potential	for	exploitation	is	high	due	to	the	immense	hope	immunotherapy	gives	to	patients.	Thus,	the	current	medical	establishment	must	proceed	with	the	interests	of	the	patient	acting	as	their	prime	motivator.	Only	through	such	a	method	will	the	full	potential	of	immunotherapy	realized.		
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